BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27223455)

  • 1. Isolated Nodal Failure after Stereotactic Body Radiotherapy for Lung Cancer: The Role for Salvage Mediastinal Radiotherapy.
    Ward MC; Oh SC; Pham YD; Woody NM; Marwaha G; Videtic GM; Stephans KL
    J Thorac Oncol; 2016 Sep; 11(9):1558-64. PubMed ID: 27223455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Horne ZD; Richman AH; Dohopolski MJ; Clump DA; Burton SA; Heron DE
    Lung Cancer; 2018 Jan; 115():1-4. PubMed ID: 29290248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
    Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
    Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results.
    Manabe Y; Shibamoto Y; Baba F; Yanagi T; Iwata H; Miyakawa A; Murai T; Okuda K
    Jpn J Radiol; 2018 Dec; 36(12):719-725. PubMed ID: 30218253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
    Parks J; Kloecker G; Woo S; Dunlap NE
    Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.
    Hearn JW; Videtic GM; Djemil T; Stephans KL
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):402-6. PubMed ID: 25017480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Schonewolf CA; Verma V; Post CM; Berman AT; Frick MA; Vachani A; Lin C; Simone CB
    Lung Cancer; 2018 Mar; 117():53-59. PubMed ID: 28800837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
    Kilburn JM; Lester SC; Lucas JT; Soike MH; Blackstock AW; Kearns WT; Hinson WH; Miller AA; Petty WJ; Munley MT; Urbanic JJ
    J Thorac Oncol; 2014 Apr; 9(4):572-6. PubMed ID: 24736084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.
    Kennedy WR; Gabani P; Nikitas J; Robinson CG; Bradley JD; Roach MC
    Radiother Oncol; 2020 Jan; 142():230-235. PubMed ID: 31481272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size.
    Marwaha G; Stephans KL; Woody NM; Reddy CA; Videtic GM
    J Thorac Oncol; 2014 Nov; 9(11):1693-7. PubMed ID: 25185531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.
    Verma V; Schonewolf CA; Cushman TR; Post CM; Doms A; Berman AT; DeVries M; Katz SI; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):502-510. PubMed ID: 30111509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Primary Surgical Resection of Non-small-cell Lung Cancer.
    Sittenfeld SMC; Juloori A; Reddy CA; Stephans KL; Videtic GMM
    Clin Lung Cancer; 2021 May; 22(3):e360-e365. PubMed ID: 32624412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer.
    Manabe Y; Shibamoto Y; Baba F; Murata R; Yanagi T; Hashizume C; Iwata H; Kosaki K; Miyakawa A; Murai T; Yano M
    Pract Radiat Oncol; 2012; 2(4):e137-e143. PubMed ID: 24674177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?
    Clarke K; Taremi M; Dahele M; Freeman M; Fung S; Franks K; Bezjak A; Brade A; Cho J; Hope A; Sun A
    Radiother Oncol; 2012 Jul; 104(1):62-6. PubMed ID: 22682749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.